New Antifungal Drugs, New Approaches and Vaccines

An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects

Phase 1

14 September 2015

A Single Ascending Dose Study of CD101 IV in Healthy Subjects

Phase 1

31 July 2015

SCYNEXIS starts phase 1 study to evaluate intravenous formulation of SCY-078

Phase 1

13 November 2015

Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis (ONICO)

Phase 4

16 November 2009

Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis

Phase 3

10 April 2007

The Novel Arylamidine T-2307 Maintains In Vitro and In Vivo Activity against Echinocandin-Resistant Candida albicans

1 December 2014

SPK 843 Kaken phase change II, Japan (mycosis).

Phase 2

9 January 2006

SPK 843 Kaken preclinical data SPA licensing offer, USA, Canada SPA phase change I, Europe.

9 October 2009

Corifungin, a New Drug Lead against Naegleria, Identified from a High-Throughput Screen

6 August 2012

Single Ascending Oral Dose Study of F901318

Phase 1

16 March 2015